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Colorectal cancer (CRC) resistance to fluoropyrimidines and other inhibitors of thymidylate synthase (TS) is a serious clinical problem
often associated with increased intracellular levels of TS. Since the tumour suppressor gene p53, which is mutated in 50% of CRC,
regulates the expression of several genes, it may modulate TS activity, and changes in the status of p53 might be responsible for
chemoresistance. Therefore, this study was aimed to investigate TS levels and sensitivity to TS inhibitors in wild-type (wt) and mutant
(mt) p53 CRC cells, Lovo and WiDr, respectively, transfected with mt and wt p53. Lovo 175X2 cells (transfected with mt p53) were
more resistant to 5-fluorouracil (5-FU; 2-fold), nolatrexed (3-fold), raltitrexed (3-fold) and pemetrexed (10-fold) in comparison with
the wt p53 parental cells Lovo 92. Resistance was associated with an increase in TS protein expression and catalytic activity, which
might be caused by the loss of the inhibitory effect on the activity of TS promoter or by the lack of TS mRNA degradation, as
suggested by the reversal of TS expression to the levels of Lovo 92 cells by adding actinomycin. In contrast, Lovo li cells, characterized
by functionally inactive p53, were 3-13-fold more sensitive to nolatrexed, raltitrexed and pemetrexed, and had a lower TS mRNA,
protein expression and catalytic activity than Lovo 92. However, MDM-2 expression was significantly higher in Lovo li, while no
significant differences were observed in Lovo 175X2 cells with respect to Lovo 92. Finally, mt p53 WiDr transfected with wt p53
were not significantly different from mt p53 WiDr cells with respect to sensitivity to TS inhibitors or TS levels. Altogether, these
results indicate that changes in the status of p53, can differently alter sensitivity to TS inhibitors by affecting TS levels, depending on
activity or cell line, and might explain the lack of clear correlation between mutations in p53 and clinical outcome after chemotherapy
with TS inhibitors.
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Thymidylate synthase (TS) is a key enzyme in the de novo
synthesis of deoxythymidine-50-monophosphate (dTMP; Carreras
and Santi, 1995), an essential precursor for DNA replication.
Therefore, one of the first rational approaches to pharmacological
treatment of colorectal cancer (CRC) was based upon fluoropyr-
imidine inhibitors of this enzyme, such as 5-fluorouracil (5-FU)
(Danenberg et al, 1999; Rose et al, 2002). A major mechanism of
resistance to 5-FU is overexpression of TS (Peters et al, 2002). At
transcriptional level, TS expression is activated by the trans-
cription factor E2F1, which plays a key role in cell cycle
progression (DeGregori et al, 1995), and appears to be inhibited
by the tumour suppressor gene p53 (Lee et al, 1997). In addition,
TS protein functions as an RNA binding protein repressing
the translation of its own mRNA (Chu et al, 1991, 1993), as well
as of that of the oncogene c-myc (Chu et al, 1995) and of p53
(Ju et al, 1999).
The relationship between p53 and TS may be altered by
mutations affecting p53, which occur in approximately 50% of
CRC (Hollstein et al, 1991; Soussi et al, 2006). Mutations in p53
have been related with resistance to chemotherapy (Lowe et al,
1993) and CRC cells with p53 mutated or disrupted through
homologous recombination were less sensitive to 5-FU (O’Connor
et al, 1997; Bunz et al, 1999). However, no clear survival benefit for
wild-type (wt) p53 was observed in our previous study of 5-FU
treated CRC patients (Van Triest et al, 2000), and the presence of
p53 mutations failed to predict which patients would benefit from
5-FU-based adjuvant chemotherapy in large retrospective clinical
trials (Allegra et al, 2003; Russo et al, 2005). Indeed, although
p53 is one of the most widely studied genes in CRC, yet there is no
single guideline in gastrointestinal oncology recommending the
routine analysis of p53 status for the assessment of drug response
(Hoff, 2005).
In the present study, we aimed to clarify the role of p53 as a
possible resistance factor for TS inhibitors. For this purpose, we
used mutant (mt) and wt p53 transfected cell lines to study the
effect of p53 mutations on TS expression and activity levels as well Revised 10 January 2007; accepted 24 January 2007
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sas on sensitivity to TS inhibitors characterized by different
mechanism of action. In particular, human CRC cell lines Lovo
92 and WiDr T and their transfected variants were exposed
to novel antifolate TS inhibitors and 5-FU, whose active metabolite
5-fluoro-20-deoxyuridine-50-monophosphate (FdUMP) competes
with dUMP, and forms a ternary complex with 5,10-methylene-
tetrahydrofolate and TS. The new antifolate TS-inhibitors include
GW1843 and the quinazoline folate analogue raltitrexed, which act
as a direct and specific TS inhibitor. The water-soluble lipophilic
nolatrexed is a direct inhibitor of TS, which does not have
glutamate side chains and can enter the cell by passive diffusion.
The multitargeted antifolate pemetrexed, inhibits a range of
enzymes involved in folate metabolism, including TS, dihydro-
folate reductase (DHFR), human monofunctional glycinamide
ribonucleotide formyltransferase, and aminoimidazole carboxa-
mide ribonucleotide formyltransferase (Rose et al, 2002; Shafran
et al, 2005).
MATERIALS AND METHODS
Drugs and chemicals
The TS inhibitors used in this study were provided by the
following persons/institutions: 5-FU by Sigma Chemicals Co.
(St Louis, MO, USA), raltitrexed by Astra-Zeneca Pharmaceuticals
(Macclesfield, UK), pemetrexed by Eli Lilly Inc. (Indianapolis, IN,
USA), GW1843U89 by Glaxo/Wellcome Co. (Research Triangle
Park, NYC, USA) and nolatrexed by Zarix, Limited (King of
Prussia, PA, USA). RNAzol was purchased from Campro Scientific
(Veenendaal, The Netherlands); Moloney Murine Leukemia Virus
Reverse Transcriptase (M-MLV-RT) from Promega (Madison, WI,
USA); deoxynucleotides (dNTPs), random hexamers and Taq
polymerase from Pharmacia Biotech (Roosendaal, The Nether-
lands). Acrylamide:bis (29:1) was purchased from Amresco
research (Solon, Ohio, USA); nitrocellulose membranes, ECL plus
and hyperfilm ECL from Amersham Life Science (Bucks, USA) and
bovine serum albumine (BSA) from Boehringer Mannheim
(Germany). Primary TS (clone 31) and p53 (Ab-2) antibodies
were obtained from Dr GW Aherne (Sutton, UK) and from
Oncogene Research products (Cambridge, MA, USA), respectively.
Horse radish peroxidase conjugated secondary antibodies were
obtained from Amersham Life Science (Bucks, PA, USA). Unless
otherwise specified, all other chemicals were of analytical grade
and commercially available.
Cell lines
The human colon carcinoma cell lines Lovo 92 and WiDr T and
their transfected variants were generously provided by Dr Poupon
(Pocard et al, 1996) and Prof. Takahashi (Tamura et al, 1995).
Lovo 92 (wt p53) and WiDr T (mt p53) are parental cell lines, and
Lovo B2 and WiDr P empty vector plasmid controls. WiDr B is
a cell line derived from WiDr T transfected with wt p53. Lovo
175X2 (mutation at position 175 (Arg-His)) cells are Lovo 92
cells transfected with mt p53. Lovo li is derived from Lovo 92 with
functional inactive p53 but without p53 mutations. Functional
activity of Lovo li was determined as described previously (Flaman
et al, 1995). Briefly, p53 mRNA of Lovo li is reverse-transcribed,
amplified by PCR, and co-transformed into yeast with an ADE2
open-reading frame under the control of a p53-responsive element.
Yeast strains with functionally active p53 express ADE2 and form
white colonies, whereas those with inactive p53 fail to express
ADE2. Consequently, they form red colonies. The yeast strain
transformed with p53 mRNA from Lovo 92 formed 15% of red
colonies and those of Lovo li, 40%. Identification of p53 mutations
was performed after sequencing of p53 exons 2–9 and exon 11.
Therefore, all exons were separately amplified using PCR (primers
available on request) as described previously by Sidransky et al
(1991) and modified by Van Houten et al (2000).
All cell lines were cultured at 371C in a 5% CO2 humidified
atmosphere in RPMI (Flow Laboratories, Irvine, Scotland)
supplemented with 10% FCS (GIBCO, Paisley, UK). Medium of
the transfected cell lines was supplemented for selection with G418
(500mgml
 1). All cell lines were growing exponentially as
monolayers during the course of all experiments. Cells used for
determination of TS expression by PCR, for TS protein expression
by western blotting and for TS catalytic and FdUMP binding assays
were harvested, frozen as cell pellets in liquid nitrogen and stored
at  801C until use.
Growth inhibition experiments
To evaluate the anti-proliferative effects of 5-FU, pemetrexed,
raltitrexed, GW1843U89 and nolatrexed, we used an MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay,
which produced similar results as a clonogenic assay (Ferreira
et al, 2001). Lovo and WiDr cells (10000cellswell
 1) were exposed
to various concentrations of TS inhibitors ranging from 10
 5 to
10
 11 M for 72h. Thereafter, medium was removed and cells were
incubated for 3h at 371Ci n5 0 ml MTT (final concentration:
0.42mgml
 1). Formazan crystals were dissolved in 150mlo f
dimethylsulfoxide and the optical density was measured at 540nm.
IC50 values were defined as the concentrations that correspond to a
reduction of cellular growth by 50% when compared to values of
untreated control cells.
Analysis of TS, DHFR and MDM-2, mRNA expression
RNA was extracted from 5 10
6 cells by the RNAzol method
and reversed transcribed by M-MLV-RT and random hexamers
as described by the manufacturer. TS mRNA expression in all cell
lines was studied by competitive template PCR (CT-PCR), using
competitive templates designed for b-actin and TS dissolved in
standardized dilutions (10
 12/10
 14,1 0
 13/10
 15,1 0
 14/10
 16 M,
respectively). cDNA samples were amplified in a MJ Research
PTC-2000 apparatus (Biozym, Landgraaf, the Netherlands) with
1min steps of denaturation at 941C, primer annealing at 581C and
elongation at 721C for 35 cycles starting with a hot start at 941C.
PCR products were separated by 130 Volt electrophoresis for 2h
on 2% agarose gels containing 0.1mgml
 1 ethidium bromide.
The intensity of the native target (NT) and template bands
was quantified by digital image analysis using Molecular Analist
(Biorad, Veenendaal, the Netherlands). Concentrations of NT
molecules of TS and b-actin in the cDNA samples were calculated
by the ratio of NT/CT after amplification and the molarity of the
CT mixture used, as described previously (Rots et al, 2000).
Additional analysis of TS and DHFR expression in the Lovo
variants was performed by real-time PCR with the Applied
Biosystems 7500HT sequence detection system (Applied Bio-
systems, Foster City, CA). Forward (F) and reverse (R) primers
and probes (P) were designed with Primer Express 2.0 (Applied
Biosystems) on the basis of TS and DHFR gene sequence obtained
from the GeneBank. PCR reactions were performed in triplicate
using 5ml of cDNA, 12.5ml of TaqMan Universal PCR Master Mix,
2.5ml of probe and 2.5ml of forward and reverse primers in a final
volume of 25ml (Giovannetti et al, 2005).
Analysis of MDM-2 expression was performed by SYBR GREEN
real-time PCR with the LightCycler Instrument (Roche
Applied Science, Mannheim, Germany), as described previously
(Slack et al, 2005).
Amplifications were normalized to b-actin, after that prelimin-
ary experiments carried out with dilutions of cDNA obtained from
Quantitative PCR Human Reference Total RNA (Stratagene,
La Jolla, CA, USA) demonstrated that the efficiencies of
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approximately equal.
Western blot analysis of TS and p53
Frozen pellets of Lovo and WiDr variants were lysed and 25mg
total protein from each cell line was loaded and separated on a 10%
SDS–PAGE gel (acrylamide:bis¼29:1) followed by blotting onto
nitrocellulose membrane. The nitrocellulose membrane was
preincubated at room temperature in blocking buffer (0.5% milk
powder, 0.5% BSA in TBS-T (10mM Tris–HCl, pH 8.0, 0.15 M
NaCl, 0.05% Tween-20)) to prevent aspecific antibody binding.
After 1h, the primary TS (1:500) and p53 (1:100) antibodies were
added and incubated overnight at room temperature (RT). After 3
washing steps of 30min in TBS-T, the blots were incubated for 1h
at RT with anti-rabbit (for TS) and anti-mouse (for p53) horse-
radish peroxidase labelled secondary antibodies (Peters et al,
2000). Detection of antibody binding was measured using
enhanced chemoluminescence (ECL plus). Densitometric analysis
of the images captured on the VersaDoc 3000 instrument (Bio-Rad,
Hertfordshire UK) was performed with the Kontron Analysis
Image software (Kontron Electronik, Munich, Germany).
FdUMP binding and TS catalytic activity
Cell pellets of Lovo and WiDr variants (20 10
6cellsml
 1) were
dissolved in an ice-cold 200mM Tris-HCl buffer (pH 7.4) contain-
ing 20mM b-mercaptoethanol, 100mM NaF and 15mM CMP. After
sonification (3 5s with intervals of 10s) and centrifugation
(14000g for 15min at 41C) the enzyme-containing suspension
was split in several parts. Fifty ml was used for determination
of the protein content according to Bradford assay. The remaining
volume was used for the FdUMP binding and TS catalytic assay
previously described by Van Triest et al (1999).
Evaluation of modulation of TS expression
To test whether the modulation of TS expression and activity could
depend on different TS regulation, Lovo 92 and Lovo175X2
exponentially growing cells were incubated in 10% FCS-RPMI
supplemented with the transcriptional inhibitor actinomycin
(Sigma), used at a non-toxic concentration of 5mgml
 1. After
4h, cells were harvested and used for analysis of TS expression by
PCR and Western blot, as described above.
Statistical analysis
Potential differences between the parental Lovo and WiDr cells and
their transfectant variants for the various parameters were
evaluated using the two-tailed unpaired Student’s t-test. Changes
were considered significantly different when Po0.05.
RESULTS
Sensitivity to TS inhibitors
To study a potential effect of p53 mutations on the sensitivity to TS
inhibitors, we performed growth inhibition experiments in several
previously transfected cells. However, as shown in Table 1, no
significant differences in doubling times were observed between
the Lovo and WiDr variants, varying from 34.5 to 46.5h. For the
empty vector plasmid control Lovo B2 and the parental cell
line Lovo 92 no significant differences (P40.05) were observed in
sensitivity for 5-FU (1.9 vs 1.7mM), nolatrexed (4.6 vs 5.1mM),
raltitrexed (21.3–30.7nM), pemetrexed (325.0–417.0nM) and
GW1843 (2.4–5.5nM), although Lovo B2 tended to be more
sensitive to all the antifolates. Lovo 175X2 (transfected with mt
p53) were more resistant compared to the wt p53 parental cell line
Lovo 92 (Po0.05); 2-fold to 5-FU, 3-fold to nolatrexed, 3-fold to
raltitrexed and 10-fold to pemetrexed. In contrast, the inactive
status of p53 in Lovo li reduced IC50 values of nolatrexed,
raltitrexed, pemetrexed and GW1843 by 3-fold, 5-fold, 4-fold and
13-fold, respectively, compared with the parental cell line.
WiDr T (mt p53) and WiDr B (transfected with wt p53) cells did
not differ with respect to sensitivity to TS inhibitors (Table 1).
Similar IC50 values of 5-FU (7.6–11.5mM), nolatrexed (1.8–2.7mM),
raltitrexed (3.7–4.7nM), pemetrexed (23.5–25.4nM) and GW1843
(0.7–1.1nM) were found in WiDr T, WiDr P and WiDr B
(P40.05).
mRNA expression of TS, DHFR and MDM-2 in wt
and mt p53 control and transfected cells
In order to determine whether p53 induced changes in TS and
DHFR that would be responsible for differences in sensitivity we
determined the mRNA expression of these factors potentially
affecting efficacy of 5-FU and antifolates using both a CT and a
real-time PCR.
The CT-PCR analysis showed that TS expression was 3-fold
higher in Lovo 92 cells (average TS/b-actin ratio of 1.7 10
 2),
compared to WiDr T (0.3 10
 2), while expression levels in all the
WiDr variants were comparable (with values ranging from 0.3 to
0.5 10
 2). Similarly, no significant differences were found
between Lovo 92 and Lovo B2, while TS expression was 1.5-fold
higher in Lovo 175X2 in comparison to Lovo 92 cells. In contrast,
Lovo li cells were characterized by a significantly reduced mRNA
expression of TS (0.4 10
 2), compared to the parental cells. Real-
time PCR analysis confirmed that Lovo li cells were characterized
by a significantly reduced mRNA expression of TS compared to
Lovo 92 cells (TS/b-actin ratio of 0.77970.030 vs 0.88070.032,
Po0.05). Moreover, TS mRNA expression was significantly
higher in Lovo 175X2 (1.04170.024) compared to Lovo 92 cells
(Figure 1). In contrast, no significant differences were observed in
DHFR mRNA expression levels in Lovo 92, Lovo 175X2 and Lovo
li cells (Figure 1).
Table 1 IC50 values of TS inhibitors and doubling times in p53 colon cancer cell lines
P53 status Doubling time (hrs) 5-FU (lM) Nolatrexed (lM) Raltitrexed (nM) Pemetrexed (nM) GW1843 (nM)
Lovo 92 wt p53; parental 34.573.4 1.7370.15 5.1570.85 30.770.7 417.0783.0 5.571.5
Lovo B2 Plasmid control 44.774.0 1.8770.58 4.5770.72 21.377.2 325.07104.1 2.470.8
Lovo 175X2 Transfected with mt p53 46.575.5 3.2570.25* 19.0071.00* 100.071.0* 3912.07138.9* 5.370.3
Lovo li Functional inactive p53 41.774.2 2.1070.40 2.1070.10* 5.770.7* 72.5712.5* 0.870.3
WiDr T mt p53; parental 36.773.7 9.3371.76 2.3070.48 4.070.4 23.374.4 0.870.1
WiDr P Plasmid control 42.072.9 11.5073.05 1.8070.10 4.771.2 23.571.5 1.170.2
WiDr B Transfected with wt p53 41.473.9 7.0072.00 2.7070.51 3.770.4 25.574.1 0.770.2
Growth inhibition was determined as described in the Materials and Methods section. IC50 values are given as mean values (in nM or mM)7standard error of the mean (s.e.m.) of
at least three experiments. Significant differences (Po0.05) between parental lines (Lovo 92 and WiDr T) and transfected cell lines are indicated with *. Nolatrexed data have
already been published and are included for comparison purposes (Backus et al, 2003).
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sAnalysis of MDM-2 gene expression status revealed that Lovo
li cells were characterized by significantly higher expression of
MDM-2 mRNA with respect to Lovo 92 cells (MDM-2/b-actin ratio
of 0.97370.007 vs 0.76070.022, Po0.05), while no significant
differences were detected in Lovo 175X2 cells.
Protein expression of TS and p53
Stable transfection of wt and mt p53 was checked by analysis of the
p53 protein expression using western blot analysis (Figure 2). As
expected, p53 expression was low in wt p53 cell lines Lovo 92 and
Lovo B2, while up-regulation was found in the mt p53 transfectants
Lovo 175X2. Hardly any p53 expression was detected in the p53
inactive cell line Lovo li. WiDr variants expressed high levels of
p53 and WiDr B presented a higher expression of p53 than WiDr
T, as detected by densitometric analysis. Western blotting also
illustrated that the p53 status was associated with changes in the
protein expression of TS. Low TS expression was detected in Lovo
92 and Lovo B2 cells, whereas an increase was found in Lovo
175X2. No TS expression was detectable in Lovo li. Low TS
expression was found in WiDr T, WiDr P and WiDr B.
FdUMP binding and TS catalytic activity
Changes in TS protein expression were accompanied with
differences in the number of FdUMP binding sites (Figure 3A)
and TS catalytic activity (Figure 3B). Lovo li had significantly less
FdUMP binding sites compared with Lovo 92, Lovo B2 and Lovo
175X2 cells. In addition, the catalytic activity of TS was about
2-fold lower in Lovo li compared with the parent cell line, while TS
activity was about 1.5 higher in Lovo 175X2 (Po0.05). The number
of FdUMP binding sites was comparable in all WiDr variants, as
well as the TS catalytic activity.
Modulation of TS expression by inhibition of transcription
To determine whether the increased TS expression in Lovo 175X2
cells was caused by modulation of transcriptional activity, cells
were treated with actinomycin, using conditions widely employed
to study inhibition of transcription. TS mRNA expression and
protein expression were compared to that observed in the parental
cell line Lovo 92. PCR analysis demonstrated that actinomycin
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Figure 1 mRNA expression of TS, DHFR and MDM-2 in Lovo 92, Lovo
175X2 and Lovo li cells. The expression was determined by real-time PCR.
Values were normalised to the simultaneously determined b-actin mRNA
expression as described in the Material and Methods. Significant differences
(Po0.05) between parental and transfected lines are indicated with *.
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Figure 2 P53 and TS protein expression in p53 transfected colon cancer
cell lines. Representative blot of at least three independent Western
blotting analyses performed as described in the Material and Methods.
WiDr cells (25mg total protein) and TS control protein (1ng) were used as
positive controls for the expression of p53 and TS, respectively. Western
blot data has already been published (Backus et al, 2003).
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Figure 3 Changes in FdUMP binding and TS catalytic activity after
transfection of mt p53 in colon cancer cells. Cell extracts were used for
determination of (A) FdUMP binding (pmolmg
 1 protein) and (B)T S
activity (nmolhmg
 1 protein). Results are given as mean values7s.e.m. of
at least three experiments. Significant differences (Po0.05) between
parental and transfected lines are indicated with *.
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ssignificantly reduced mRNA TS expression in Lovo 175X2 cells,
while a slight decrease of mRNA TS was observed in Lovo 92 cells
(Figure 4A), suggesting that TS mRNA degrades at a faster rate in
Lovo 175X2 cells as compared to Lovo 92 cells. These results were
consistent with those of Figure 4B, showing that TS protein levels
were minimally modulated in Lovo 92 cells, whereas TS levels were
significantly reduced by actinomycin in Lovo 175X2 cells.
DISCUSSION
This study demonstrates that changes in the status of p53 due to
mutations or inactivity can alter sensitivity to TS inhibitors such
as 5-FU and antifolates. Sensitive p53 inactive Lovo cells had low
levels of TS whereas high TS levels were found in resistant mt p53
cells. However, transfection of wt p53 in mt p53 cells had no effect
on TS levels and hence, also on sensitivity.
Mutations in the tumour suppressor gene p53 have been related
with chemoresistance (Lowe et al, 1993) and mt p53 cells in the
NCI cell line panel were less sensitive to 5-FU (O’Connor et al,
1997). In addition, in a panel of 14 colon cancer cell lines we
observed that cells with a p53 mutation were more resistant to
5-FU and raltitrexed (Peters et al, 2002). In the present study, Lovo
cells transfection with mt p53 increased TS mRNA and protein
expression and activity which were associated with a decreased
sensitivity to 5-FU and antifolates compared to the wt parental cell
line Lovo 92. The increase in TS levels might be caused by the loss
of the inhibitory effect of wt p53 on the promoter activity of TS as
demonstrated by Lee et al (1997) suggesting that in Lovo 175X2
cells mt p53 interferes with the function of wt p53 in a dominant
negative fashion (Fearon and Vogelstein, 1990). In the present
study, the addition of the transcriptional inhibitor actinomycin in
Lovo 175X2 cells caused a significant greater reduction of TS
expression with respect to Lovo 92 cells, suggesting the occurrence
of different rates of TS mRNA degradation.
On the other hand, sensitivity to 5-FU and antifolates in the CRC
cells used in this study was not correlated with DHFR mRNA
expression, whose levels were unchanged in Lovo 92, Lovo 175X2
and Lovo li cells. Similarly, resistance to the antifolates is probably
not caused by the reduced folate carrier (RFC) and folylpoly-
glutamate synthetase (FPGS), both important for the activity of
raltitrexed and pemetrexed (Peters and Jansen, 1996), because
for nolatrexed, which is a RFC and FPGS independent specific TS
inhibitor, IC50 values were also increased. In contrast to the mt
p53 Lovo 175X2, functionally inactive p53 in Lovo li increased
sensitivity to TS inhibitors, which was associated with a decrease
in TS mRNA, protein and activity levels. Because we did not find
p53 mutations in the analysed exons of Lovo li, we can only
hypothesize that other mechanisms may be involved in the
modulation of p53 activity in these cells. The effect of p53
suppressor gene can be influenced by modifications in the gene
itself, but also by post-transcriptional modifications such as
phosphorylation and changes in physical conformation, or by
interaction with other cellular proteins, such as MDM-2 oncogene
protein (Hupp et al, 1992; Finlay, 1993) Therefore, we studied
MDM-2 gene expression and we showed that Lovo li cells were
characterized by significantly higher expression of MDM-2.
Previous studies demonstrated that MDM-2 overexpression can
block the p53-mediated transactivation, depriving p53 gene of
antineoplastic activity (Lev Bar-Or et al, 2000), and the use of anti-
sense MDM-2 had a co-operative growth-inhibitory effect with
different classes of cytotoxic drugs in colon cancer cells (Tortora
et al, 2000). However, Lovo 175X2 cells had MDM-2 expression
values similar to Lovo 92 cells, and several studies demonstrated
that oncoviral proteins, such as adenovirus El B protein and
human papilloma virus E6 protein (Lane and Benchimol, 1990) as
well as altered phosphorylation pattern (Satyamoorthy et al, 2000),
nuclear exclusion and sequestration in the cytoplasm can also
affect the normal function of p53 (Moll et al, 1992).
These results might also explain why immunohistochemistry of
p53 is not always associated with survival benefit in colorectal
cancer patients treated with 5-FU based chemotherapy (Van Triest
et al, 2000), although the lack of relationship with clinical outcome
may also be related to the discrepancy between p53 immunostain-
ing and mutation analysis (Momand et al, 1992). Immunostaining
for p53 is positive for up-regulated p53, but it may or may not
reflect a mutated status of the protein (Lenz et al, 1998; Kressner
et al, 1999).
A large number of important genetic determinants have been
identified thus far in tumours but only a few of them (TS and
dihydropyrimidine dehydrogenase) have been tested prospectively
(Smorenburg et al, 2006). The prognostic value of specific tumour
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Figure 4 Changes in TS mRNA and protein expression after treatment
with actinomycin in parental wt p53 (Lovo 92) and transfected mt p53
(Lovo 175X2) colon cancer cells. Analysis of (A) mRNA and (B) protein
expression were performed with real time with quantitative PCR and
Western blot, respectively. (C) Representative plot of Western blot
analyses performed as described in the Material and Methods. Significant
differences (Po0.05) between control and treated cells are indicated with *.
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smarkers may have been limited up to now by the (1) the small
number of patients screened and marked variability in analytical
methodology (Van Triest et al, 2000) and lack of quality controls
among different studies due to the difficulties in obtaining suitable
tissue samples; and (2) the lack of prospective trials and studies
primarily designed to detect specific correlations between gene
abnormalities and drug activity (Peters et al, 2004). The tumour
suppressor gene p53 represents a sound example of the proble-
matic link between the choice of reference methodology and the
determination of clinical utility. This gene may be analysed by
different methods, including sequencing, fluorescence in situ
hybridisation and immunohistochemistry, which may show
different results, and, even for a single type of analysis, the
specific methodological procedure and the interpretation criteria
may be subjected to considerable variability (Hoff, 2005; Van
Triest et al, 2000; Soussi et al, 2006). A large number of articles
show a variable role of p53, possibly depending on tumour type
and the type of treatment. It has been suggested that p53 gene
mutation is a significant and independent predictor of poor
prognosis in CRC (Russo et al, 2005), but we lack validation in
prospective clinical trials as a marker for the assessment of
prognosis in CRC patients (Hoff, 2005). Similarly, because of the
lack of preclinical studies to evaluate correlations between gene
abnormalities and the cytotoxic effect of the most commonly used
anticancer drugs, there is no single guideline recommending the
analysis of p53 status to predict response to specific drugs.
In this study we showed that mutations in p53 have differential
effects on sensitivity to TS inhibitors, which may influence
response and survival after chemotherapy with TS inhibitors. In
addition, inactive p53 cells with low p53 expression also have an
effect on TS and possibly on clinical outcome. However, in
agreement with several studies which demonstrated that p53
mutants were refractory to reactivation to the wt p53 pheno-
type (Kern et al, 1992; Sigal and Rotter, 2000), transfection of
wt p53 in the mt p53 cell line WiDr had no effect on sensitivity
to TS inhibitors and TS activity, suggesting that the function
of p53 could not be restored after transfection of wt p53 in mt
p53 cells.
Therefore, these results indicate that changes in the status of p53
due to mutations or functional inactivity change the sensitivity to
TS inhibitors by altering the expression and activity of TS. The
increase and decrease in sensitivity to TS inhibitors in vitro might
explain why no clear correlation was found in clinical studies
between mutations in p53 and clinical outcome. In conclusion, p53
is an important tumour suppressor gene that deserves additional
investigation as a marker of therapeutic activity in CRC, and
results obtained in the present study suggest that analysis of the
exact status of p53 (e.g. wt or mt and functionally active or not)
could be useful to predict clinical outcome after chemotherapy
with TS inhibitors.
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